Crinetics Pharmaceuticals earned FDA approval for Palsonify, an oral once-daily treatment for acromegaly in adults ineligible for or unresponsive to surgery. Clinical trials demonstrated significant reductions in growth hormone levels with favorable safety profiles. Despite approval, Palsonify faces competition from established pharma players Novartis and Ipsen who market blockbuster acromegaly medicines. Crinetics CEO Scott Struthers emphasized the milestone as transformational for patients and the company, highlighting commitment to improving lives through rare endocrine disorder therapeutics.